Evidence map›Paper›PMID 38633403›Full record

ArticleAnnals of clinical and medical case reports2024

Age, Gender, and Liver Enzyme Impact Hospital Stay in COVID-19 Minority Patient with Cancer in the USA: Does Race Matters in the Pandemic?

H Ashktorab, G Oskrochi, S R Challa, L G Chirumamilla, S Saroya, S Dusmatova, N Shayegh, V Nair, K Senthilvelan, D Byer and 12 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Annals of clinical and medical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 2 countries.

H AshktorabDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
G OskrochiCollege of Engineering and Technology, American University of the Middle East, Kuwait.
S R ChallaDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
L G ChirumamillaDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
S SaroyaDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
S DusmatovaDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
N ShayeghDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
V NairDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
K SenthilvelanDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
D ByerDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
N MorrisonDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
B GrossiDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
A BarclayDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
T SmithDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
K WatsonDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
M RashidDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
R RashidDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
M DeverapalliDepartment of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington DC, USA.
G LatellaGastroenterology Unit, Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
J M CarethersDivision of Gastroenterology & Hepatology, Department of Medicine and Moores Cancer Center, UC San Diego, USA.
A YoussefDivision of Gastroenterology and Hepatology, Department of Internal Medicine; Department of Human Genetics and Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
H BrimDepartment of Pathology and Cancer Center, Department of Biochemistry & Molecular Biology, Howard University College of Medicine, Washington DC, USA.
American University of the Middle East · KWUniversity of L'Aquila · IT

Funding

PROTEOMICS CORE FACILITYG12MD007597 · NIMHD · HOWARD UNIVERSITY · PI SOUTHERLAND, WILLIAM M. · 2012 to 2018
$14.8M
Inactivation of MSH3 in Colorectal Cancer and RaceR01CA258519 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ASHKTORAB, HASSAN, CARETHERS, JOHN M · 2021 to 2025
$2.9M
NCI NIH HHS R01 CA258519NIMHD NIH HHS G12 MD007597
6 · The paper itself

Abstract

Patients with cancer are known to have a poor prognosis when infected with SARS-CoV-2 infection. We aimed in this study to assess health outcomes in COVID-19 patients with different cancers in comparison to non-cancer COVID-19 patients from different centers in the United States (US). We evaluated medical records of 1,943 COVID-19 Cancer patients from 3 hospitals admitted between December 2019 to October 2021 and compared them with non-cancer COVID-19 patients. Among 1,943 hospitalized COVID-19 patients, 18.7% (n=364) have an active or previous history of cancer. Among these 364 cancer patients, 222 were African Americans (61.7%) and 121 were Caucasians (33.2%). Cancer patients had significantly longer hospitalization compared to controls (8.24 vs 6.7 days). Overall, Lung cancer is associated with high mortality. Patients with a previous history of cancer were more prone to death (p=0.04) than active cancer patients. In univariate and multivariate analyses, predictors of death among cancer patients were male sex, older age, presence of dyspnea, elevated troponin, elevated AST (0.001) and ALT (0.05), low albumin (p=0.04) and mechanical ventilation (p=0.001). Patients with a previous history of cancer were more prone to death when compared to active cancer COVID-19 patients. Early recognition of cancer COVID-19 patients' death-associated risk factors can help determine appropriate treatment and management plans for better prognosis and outcome.

Indexed as

African AmericanCancerCoronavirus (COVID-19)Mortality

Identifiers

PMID38633403
PMCPMC11022387
OpenAlexW4394920572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.